tbuckley/cabot-search huggingface dataset:
Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline characteristics of 10,124 patients (pts).
Authors: J. R. Zalcberg, K. M. Mohandas, Y. Kang, Y. Bang, M. Ter-Ovanesov, S. Ben Ahmed, C. Wu, A. Roth, E. B. Ecstein-Fraïssé, S. Yalcin
Journal: Journal of Clinical Oncology (2010)

4082 Background: Gastric cancer (GC) is the second leading cause of cancer death worldwide and has a variety of risk factors. The REGATE international disease registry was designed to describe the geographic pattern of pt and tumor characteristics, as well as treatment of GC in order to improve pt care. Methods: Pts with newly diagnosed primary GC were enrolled from August 2004 to July 2008; data were collected at an initial visit and < 10 months later. The target sample size was calculated according to the GC prevalence in the participating countries. Baseline characteristics of pts are described according to region. Staging, diagnosis, surgical and other treatments are reported elsewhere. Results: Analyses were performed for 10,124 pts enrolled in 22 countries: Europe (E) 32%, Asia-Pacific (AP) 31%, Latin America (LA) 20%, Indian subcontinent (IS) 12%, and North Africa (NA) 6%. The majority of pts in all regions (60%–71%) were men. Median age was lower on the IS and in NA (53 years) than in E, LA, and AP (61–62) with 38%–42% of pts on the IS and in NA aged < 50 years. During their clinical investigations, more pts in LA (79%) and E (71%) had endoscopy than in AP (56%), NA (50%) and the IS (47%). Family history of GC was assessed in 57%–88% of pts, it was most common in LA (14%) and rare on the IS (2%), compared with 8% of pts globally. H. pylori infection was investigated more often in AP (48%) and LA (41%) than in E (16%), the IS (15%), and NA (12%). In AP, 18% of pts were asymptomatic compared with 9% in the whole population. Median time (days) from first symptoms to diagnosis was shorter in AP (60) than in E (90), LA (120), NA (120), and on the IS (150). Endoscopy was the most frequently used technique for diagnosis (95%) in all areas. Planned therapy was primarily based on GC stage (69%) in all regions, ranging from 56% (LA) to 79% (AP). The choice of treatment was driven mostly by a multidisciplinary team on the IS (50%), in LA (56%), and in NA (60%) and mainly by surgeons in E (40%) and AP (49%). Conclusions: Baseline characteristics of pts with GC in the REGATE registry differ among geographic regions, particularly with respect to the presence of GC symptoms, the time to diagnosis, and the medical professionals driving treatment decisions. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis sanofi-aventis sanofi-aventis sanofi-aventis
Epidémie d'intoxications alimentaires à Salmonella enteritidis provenant d'un fromage de fabrication industrielle
Authors: M. G. Panico, F Primiano, F Nappi, F Attena
Journal: Eurosurveillance (1999)

Entre le 30 juin et le 2 juillet 1998, trois hopitaux ont declare neuf cas suspects d’intoxications alimentaires au service d’epidemiologie et de prevention (Servizio di Epidemiologia e Prevenzione - SEP) des autorites sanitaires locales de la region de Naples (Azienda Sanitaria Locale, ASL NA 4). Le SEP debuta aussitot une enquete.
<i>nab</i>-paclitaxel (<i>nab</i>-P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
Authors: Irfan Firdaus, David Michael Waterhouse, Martin Gutierrez, Zev A. Wainberg, Ben George, Karen Kelly, Tanios S. Bekaii-Saab, Daniel R. Carrizosa, Hatem Hussein Soliman, Cindy Duval Fraser, Amy Ko, Daniel W Pierce, Victoria G. Manax, Sotirios G. Stergiopoulos, Howard S. Hochster
Journal: Journal of Clinical Oncology (2016)

TPS475 Background: Nivo, an antibody against PD-1, is approved for unresectable or metastatic melanoma and metastatic squamous non-small cell lung cancer (NSCLC) after initial standard therapies. nab-P does not require immunosuppressive steroid premedication and is approved for treatment of metastatic breast cancer (MBC) after initial chemotherapy (CT) including an anthracycline, and for advanced NSCLC (+ carboplatin), and metastatic PC (+ Gem). This 6-arm, multicenter phase I trial will evaluate the safety of Nivo with nab-P— based therapy in MBC, advanced NSCLC, and advanced PC. The study design for the pancreatic portion (arm A: nab-P + Nivo; arm B: nab-P + Gem + Nivo) is described below. Methods: This 2-part study will identify dose-limiting toxicities (DLTs) in Part 1 and assess safety and explore antitumor activity in Parts 1 and 2 (Table). If Arm A, Part 1, is deemed safe (≤ 1 DLT in up to 6 pts), then Arm B, Part 1, will initiate enrollment. Regimens in Part 1 may be expanded in Part 2. Enrollment in Arm A, Part 1, is ongoing. ClinicalTrials.gov: NCT02309177. Clinical trial information: NCT02309177. [Table: see text]
Clopidogrel pretreatment does not influence the relative efficacy of bivalirudin with provisional GPIIb/IIIa blockade vs heparin with routine GPIIb/IIIa blockade. A REPLACE-2 substudy
Authors: J Saw, Walter Desmet, AM Lincoff, A Betriu, W Rutsch, RG Wilcox, NS Kleiman, EJ Topol
Journal: Circulation (2003)
Efficacy and safety of bevacizumab plus irinotecan in patients with recurrent malignant poor-prognosis glioma.
Authors: J. Pichler, S. Nöbauer, J. Buchroitner, W. Wies, G. Wurm, S. Wimmer, J. Trenkler, J. Fischer
Journal: Journal of Clinical Oncology (2010)

e12555 Background: There is currently no standard of care for recurrent glioblastoma multiforme (GBM), although the anti-VEGF monoclonal antibody bevacizumab (Bev) has shown efficacy in conjunction with irinotecan (Iri). We present a retrospective analysis of patients with recurrent malignant brain tumors treated with Bev-Iri at our clinic. Methods: 37 adult patients with recurrent malignant brain tumors were included. Patient characteristics: median age 46 years, GBM diagnosis n = 26, other brain tumor histology n = 11. Prior surgery n = 34, prior chemotherapy n = 37, prior radiotherapy n = 32. Patients received Bev 10 mg/kg i.v. and Iri 125 mg/m2 i.v. (340 mg/m2 in one patient receiving enzyme-inducing antiepileptic drugs) every 14 days. Treatment was stopped on progression, patient's wish or physician's decision. Response was assessed using MacDonald's criteria on post-contrast MRI with inclusion of FLAIR, T2 and perfusion-weighted MRI. Adverse events (AEs) were monitored throughout therapy. Results: Patients received a median of 7 cycles of Bev-Iri (range 3–15) and 8 patients received maintenance Bev until progression. 26 patients (70%) achieved a complete or partial response with Bev-Iri, and 4 (11%) had stable disease. Median time to progression was 5.8 months (range 1.4–not reached) and median overall survival was 11.1 months (range 2.7–not reached) without difference between GBM patients and the group with other types of malignant brain tumors. The bevacizumab/irinotecan combination was well tolerated, with few grade 3 AEs (8 lymphocytopenia, 2 leucocytopenia, 1 diarrhea); there were no AEs of grade > 3. The most common grade 1–2 AEs were leucocytopenia (n = 7), hypertension (n = 5) and lymphocytopenia (n = 4). Conclusions: Our data show that bevacizumab plus irinotecan is an effective combination for recurrent malignant brain tumors and correspond with Phase II data for this strategy. The median overall survival of over 11 months in our study represents a considerable improvement in prognosis for these patients and warrants a larger, more thorough prospective exploration of this combination. The potential for bevacizumab-containing maintenance regimens also exists. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche
Impact of therapy on gene expression in high-risk prostate cancer (PCA) treated with neoadjuvant docetaxel and androgen deprivation therapy.
Authors: Himisha Beltran, Alexander Wyatt, Edmund Chedgy, Ladan Fazli, Andrea Sboner, Susan Halabi, Martin Gleave
Journal: Journal of Clinical Oncology (2016)

8 Background: Molecular analyses of neoadjuvant post-treatment radical prostatectomy (RP) specimens has been challenging as often times only microscopic foci remain present at time of RP precluding RNA-seq. DNA analysis alone in the absence of expression may be suboptimal in elucidating complex mechanisms of resistance and/or prognostic risk stratification. We therefore set out to develop an assay that could quantify mRNA expression in treated and untreated PCA using formalin fixed paraffin embedded (FFPE) tissues. Methods: We evaluated 40 untreated and post-treatment FFPE specimens as well as patient-matched pre-treated needle biopsies and baseline clinical data from patients enrolled on CALGB 90203: a randomized phase 3 trial comparing noeadjuvant docetaxel and ADT followed by RP vs RP alone for men with high risk localized PCA. High-density tumor areas were selected for RNA extraction (min 50ng RNA). We used NanoString nCounter to quantify gene expression of a custom panel of 75 genes including AR and androgen regulated, neural/neuroendocrine (NE), EMT, cell cycle, hormone receptors, TMPRSS-ERG, ARv7 splice variant, and housekeeper genes. mRNA data was integrated with matched whole exome sequencing data. Frozen specimens and RNA-Seq (n = 7) were used for QC and comparative analysis. Results: Quantitative expression using Nanostring showed high correlation with RNA-seq of patient-matched frozen tissue (Spearman coefficient 0.9). There was significant upregulation of AR and the ARv7 expression following treatment, as well as a subset of NE and EMT genes; three high chromogranin A outlier cases were identified in the treatment arm. There was an overall higher AR score in treated cases (based on expression of 30 AR signaling genes) compared to untreated, along the spectrum of CRPC. Conclusions: These data support the feasibility of quantifying gene expression in neoadjuvant-treated PCA cases with limited FFPE tissue requirement. Extensive characterization of AR status and NE/EMT genes identifies molecular outliers that can arise post-treatment and provides new insight into the heterogeneity of treatment response and potential early markers of resistance. Clinical trial information: NCT00430183.
Optimization of Gross Tumour Volume Definition in Lung-Sparing Volumetric Modulated Arc Therapy for Pleural Mesothelioma
Authors: Angela Botticella, Gilles Defraene, Kristiaan Nackaerts, Christophe Deroose, Johan Coolen, Philippe Nafteux, Stéphanie Peeters, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2015)
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
Authors: Ying Sun, Wen-Fei Li, Nian-Yong Chen, Ning Zhang, Guo-Qing Hu, Fang-Yun Xie, Yan Sun, Xiao-Zhong Chen, Jin-Gao Li, Xiao-Dong Zhu, Chao-Su Hu, Xiang-Ying Xu, Yuan-Yuan Chen, Wei-Han Hu, Ling Guo, Hao-Yuan Mo, Lei Chen, Yan-Ping Mao, Rui Sun, Ping Ai, Shao-Bo Liang, Guo-Xian Long, Bao-Min Zheng, Xing-Lai Feng, Xiao-Chang Gong, Ling Li, Chun-Ying Shen, Jian-Yu Xu, Ying Guo, Yu-Ming Chen, Fan Zhang, Li Lin, Ling-Long Tang, Meng-Zhong Liu, Jun Ma
Journal: The Lancet Oncology (2016)
Myocardial Phosphodiesterase 5 Expression Contributes to Left Ventricular Dysfunction in the Pressure-Overloaded Heart
Authors: Sara Vandenwijngaert, Peter Pokreisz, Marijke Pellens, Hilde Gillijns, Tom Dresselaers, Paul Veulemans, Xiaoshun Liu, Paul Herijgers, Uwe Himmelreich, Jan D'hooge, Kenneth Bloch, Stefan Janssens
Journal: Circulation (2009)
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Authors: F. Husseini, J.-P. Delord, C. Fournel-Federico, J. Guitton, P. Erbs, M. Homerin, C. Halluard, C. Jemming, C. Orange, J.-M. Limacher, J.-E. Kurtz
Journal: Annals of Oncology (2016)
Adenomyomatous hyperplasia of the lower bile duct mimicking a papillary bile duct tumor
Authors: Yoshikuni Nagashio, Terumasa Hisano, Yoshifusa Aratake, Eiji Tsujita, Fumiyoshi Fushimi, Kenichi Taguchi, Masayuki Furukawa
Journal: Endoscopy (2016)

Adenomyomatous hyperplasia is an extremely rare benign lesion of the hepatobiliary tract, including the ampulla of Vater, with most cases described in the gallbladder [1] [2] [3] [4]. However, its importance lies in its ability to mimic bile duct tumors [1] [2].
Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial
Authors: Anne E Holland, Ajay Mahal, Catherine J Hill, Annemarie L Lee, Angela T Burge, Narelle S Cox, Rosemary Moore, Caroline Nicolson, Paul O'Halloran, Aroub Lahham, Rebecca Gillies, Christine F McDonald
Journal: Thorax (2016)

<h3>Background</h3> Pulmonary rehabilitation is a cornerstone of care for COPD but uptake of traditional centre-based programmes is poor. We assessed whether home-based pulmonary rehabilitation, delivered using minimal resources, had equivalent outcomes to centre-based pulmonary rehabilitation. <h3>Methods</h3> A randomised controlled equivalence trial with 12 months follow-up. Participants with stable COPD were randomly assigned to receive 8 weeks of pulmonary rehabilitation by either the standard outpatient centre-based model, or a new home-based model including one home visit and seven once-weekly telephone calls from a physiotherapist. The primary outcome was change in 6 min walk distance (6MWD). <h3>Results</h3> We enrolled 166 participants to receive centre-based rehabilitation (n=86) or home-based rehabilitation (n=80). Intention-to-treat analysis confirmed non-inferiority of home-based rehabilitation for 6MWD at end-rehabilitation and the confidence interval (CI) did not rule out superiority (mean difference favouring home group 18.6 m, 95% CI −3.3 to 40.7). At 12 months the CI did not exclude inferiority (−5.1 m, −29.2 to 18.9). Between-group differences for dyspnoea-related quality of life did not rule out superiority of home-based rehabilitation at programme completion (1.6 points, −0.3 to 3.5) and groups were equivalent at 12 months (0.05 points, −2.0 to 2.1). The per-protocol analysis showed the same pattern of findings. Neither group maintained postrehabilitation gains at 12 months. <h3>Conclusions</h3> This home-based pulmonary rehabilitation model, delivered with minimal resources, produced short-term clinical outcomes that were equivalent to centre-based pulmonary rehabilitation. Neither model was effective in maintaining gains at 12 months. Home-based pulmonary rehabilitation could be considered for people with COPD who cannot access centre-based pulmonary rehabilitation. <h3>Trial registration number</h3> NCT01423227, clinicaltrials.gov.
P3-229: Is there still a place for surgery in the treatment of locally advanced non-small cell lung cancer (IIIA, N2)?
Authors: Ingrid Kappers, Nico v. Zandwijk, Jose S. Belderbos, Michel J. Wouters, Jacobus A. Burgers, Houke M. Klomp
Journal: Journal of Thoracic Oncology (2007)
ASSOCIATIONS BETWEEN GERMLINE GENOTYPE AND EFFICACY AND SAFETY OUTCOMES IN A PHASE III STUDY OF SUNITINIB AND FOLFIRI IN METASTATIC COLORECTAL CANCER (MCRC)
Authors: Eric Van Cutsem, Feng Gao, Jodi Richmond, James Williams, Xun Lin, Derek Jonker, Yan Sun, Jhony De La Cruz, Jennifer Tursi, Maria Jose Lechuga, Alfredo Carrato
Journal: Annals of Oncology (2011)
Effect of Glioma N-Myc downstream regulated gene 1 (NDRG1) on the tumor microenvironment.
Authors: Carina Thomé, Jonas Blaes, Petra Rübmann, Jana Sonner, Katrin Deumelandt, Matthias Osswald, Manfred Jugold, Michael Breckwoldt, Thomas Broggini, Marcus Czabanka, Peter Vajkoczy, Frank Winkler, Michael Platten, Wolfgang Wick
Journal: Journal of Clinical Oncology (2016)

11587 Background: Malignant glioma belongs to the most aggressive neoplasms in humans. They are highly invasive and the cellular and genetic inter- and intratumor heterogeneity contributes to treatment resistance. The interactions and intercellular communications between malignant and non-malignant cells in the tumor microenvironment are deemed tumor-promoting and critically to improve the understanding of the disease. N-myc downstream regulated gene 1 (NDRG1) is a stress inducible gene and key determinant of resistance towards alkylating chemotherapy in glioblastoma. Methods: To analyze the NDRG1 effects on the brain tumor microenvironment, we used a human NDRG1 knockdown (KD) glioma model system. In orthotopic xenograft experiments control and KD microenvironments were compared for angiogenesis and infiltrating immune cells dependent on NDRG1. Clodronate liposomes were used to deplete macrophages. In vitro and in vivo angiogenesis assays were used to assess neovascularization. Results: Orthotopic tumors showed significant volume differences between control and NDRG1 KD implanted cells and demonstrated a markedly increased vessel density in the NDRG1 KD microenvironment. Ex vivo flow cytometry analyses of the tumor stromal cells revealed a significant increase in peripheral macrophages in NDRG1 KD microenvironment compared to the control microenvironment. The same was shown for dendritic cells as well as for monocytic myeloid derived suppressor cells (MDSCs). Depletion of macrophages however did not alter tumor growth of NDRG1 KD tumors. Cytokine array analysis on U87MG NDRG1 KD and control supernatants showed a marked increase in CCL2 secretion in the NDRG1 KD cells. Macrophages showed an increased migration rate towards NDRG1 knockdown environment in vitro. Conclusions: Glioma NDRG1 shapes the tumor microenvironment by regulating angiogenesis and influences macrophage recruitment in vivo and in vitro. CCL2 was identified as a relevant cytokine dependent of the NDRG1 status in this human glioma model. These data could help to better understand the relationship between NDRG1 and the tumor microenvironment.
Painless Vesicular Eruption on the Dorsal Surfaces of the Hands
Authors: Allen Shih, William Damsky, Amanda Zubek
Journal: JAMA (2016)

A 67-year-old man with a history of heavy smoking and alcohol consumption presented with painless vesicles and milia on the dorsal surfaces of the hands. Results of a basic laboratory tests were normal; liver function tests revealed elevated levels of bilirubin, AST, and ALT. What would you do next?
Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma
Authors: M.A. Pizzichetta, H. Kittler, I. Stanganelli, G. Ghigliotti, M.T. Corradin, P. Rubegni, S. Cavicchini, V. De Giorgi, R. Bono, M. Alaibac, S. Astorino, F. Ayala, P. Quaglino, G. Pellacani, G. Argenziano, D. Guardoli, F. Specchio, D. Serraino, R. Talamini
Journal: British Journal of Dermatology (2016)

In addition, irregular brown globules/dots and white shiny lines can also be observed, as clue features to add to the above cited criteria in differentiating AHNM from other lesions.
Pediatric Idiopathic Intracranial Hypertension
Authors: Claire A. Sheldon, Grace L. Paley, Rui Xiao, Anat Kesler, Ori Eyal, Melissa W. Ko, Chantal J. Boisvert, Robert A. Avery, Vincenzo Salpietro, Paul H. Phillips, Gena Heidary, Shana E. McCormack, Grant T. Liu
Journal: Ophthalmology (2016)
P0024 : Efficacy of wharton’s jelly-derived mesenchymal stem cells combined with praziquantel in schistosoma mansoni-induced liver fibrosis in mice
Authors: O.A. Hammam, N. Elkhafif, Y.M. Attia, T. Mansour, M.M. Elmazar, R.A. Mohsen, S. Kenawy, A.S. El Khatib
Journal: Journal of Hepatology (2015)
Circulating tumor DNA (ctDNA) to track responses and to capture the genomic heterogeneity of metastatic melanoma.
Authors: Shahneen Kaur Sandhu, Stephen Q Wong, Ismael A. Vergara, Jeanette Raleigh, Jason Callahan, Sarah Ftouni, Athena Hatzimihalis, Sinha Devbarna, Ken Doig, Andrew Colebatch, Gisela MirArnau, Carleen Cullinane, David E. Gyorki, Damien Kee, Benjamin M. Brady, Mark J. Shackleton, Anthony Papenfuss, Rodney J Hicks, Grant A. McArthur, Sarah-Jane Dawson
Journal: Journal of Clinical Oncology (2016)

9582 Background: While immunotherapy and MAPK-targeted therapies have improved patient outcome, the genomic heterogeneity of melanoma contributes to treatment resistance. Molecular approaches for monitoring tumor burden, treatment response and resistance has enormous potential. ctDNA may allow global representation of all disease sites, and serial ctDNA analysis can track responses and provide insights into the spatio-temporal profile of the disease. Methods: Fifty-two metastatic melanoma patients (pts) were serially monitored during sequential lines of therapy with FDG-PET scans, LDH and ctDNA. Serial tumor biopsies were collected. Five of these 52 pts consented to multiregional tumor sampling at autopsy. Allele specific digital PCR assays, customized targeted and whole exome sequencing was used to measure ctDNA levels and identify genomic alterations. Results: In BRAF and NRAS mutant patients, mutant ctDNA was detected in 72% of patients at baseline and encompassed between 0.4%-86% (median 8.2%) of total ctDNA levels. LDH and FDG-PET metabolic tumor volume correlated significantly with mutant BRAF and NRAS copies in plasma [(r=0.7818, p=0.0032) and (r=0.63, p=0.0001) respectively]. High ctDNA levels were associated with worse overall survival. ctDNA levels tracked with FDG-PET responses. Targeted sequencing of baseline ctDNA and tumor samples identified multiple mutations in clinically important genes such as MAP2K1, MAP2K2, PTEN, CDKN2A, RAC1, CTNNB1,BRAF and NRAS; high concordance was observed between ctDNA and tumor. ctDNA analysis also identified multiple mutations associated with primary and acquired resistance to MAPK-targeted therapy. Comprehensive exome sequencing of ctDNA in patients undergoing autopsy provided an accurate representation of spatial heterogeneity, when compared to multi-regional tumor sequencing. Conclusions: These findings highlight the potential clinical utility of ctDNA analysis to monitor tumor responses and disease progression in the management of metastatic melanoma patients.
α3β1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway
Authors: Afshin Varzavand, Will Hacker, Deqin Ma, Katherine Gibson-Corley, Maria Hawayek, Omar J. Tayh, James A. Brown, Michael D. Henry, Christopher S. Stipp
Journal: Cancer Research (2016)

Existing anticancer strategies focused on disrupting integrin functions in tumor cells or tumor-involved endothelial cells have met limited success. An alternative strategy is to augment integrin-mediated pathways that suppress tumor progression, but how integrins can signal to restrain malignant behavior remains unclear. To address this issue, we generated an in vivo model of prostate cancer metastasis via depletion of α3β1 integrin, a correlation observed in a significant proportion of prostate cancers. Our data describe a mechanism whereby α3β1 signals through Abl family kinases to restrain Rho GTPase activity, support Hippo pathway suppressor functions, and restrain prostate cancer migration, invasion, and anchorage-independent growth. This α3β1-Abl kinase-Hippo suppressor pathway identified α3 integrin-deficient prostate cancers as potential candidates for Hippo-targeted therapies currently under development, suggesting new strategies for targeting metastatic prostate cancer based on integrin expression. Our data also revealed paradoxical tumor suppressor functions for Abl kinases in prostate cancer that may help to explain the failure of Abl kinase inhibitor imatinib in prostate cancer clinical trials. Cancer Res; 76(22); 6577-87. ©2016 AACR.